Literature DB >> 17922126

Extracellular signal-regulated kinase phosphorylation due to menadione-induced arylation mediates growth inhibition of pancreas cancer cells.

Shinji Osada1, Fumio Sakashita, Yosiki Hosono, Kenichi Nonaka, Yasuharu Tokuyama, Hidenori Tanaka, Yoshiyuki Sasaki, Hiroyuki Tomita, Shuji Komori, Satoshi Matsui, Takao Takahashi.   

Abstract

BACKGROUND: Cytotoxicity of Vitamin K3 (VK3) is indicated to have the same mechanism with oxidative stress (H(2)O(2)). In the present study, we analyzed the differences and/or similarities in the cellular responses to oxidative stress and VK3 to clarify the mechanism of growth inhibition.
METHODS: Cell viability was determined by a test method with 3-[4, 5-dimethyl-thiazol]-2, 5-dephenyl tetrazolium bromide (MTT). Expressions of cellular proteins were evaluated by Western blot analysis.
RESULTS: The IC50 was calculated to be 47.3 +/- 4.1 microM for VK3 and 2.2 +/- 1.2 microM for H(2)O(2). By Western blot analysis, VK3 or H(2)O(2) was shown to induce rapid phosphorylation of extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinases (JNKs). H(2)O(2)-induced phosphorylation of ERK and JNK was almost complete inhibited by more than 100-muM genistein. VK3-induced JNK phosphorylation was blocked by 100-microM genistein, but ERK phosphorylation was not inhibited completely even if 400-microM genistein was used. H(2)O(2)-induced inhibition of cell proliferation was completely blocked by 400-microM genistein, but the VK3 effect was reduced 72.8 +/- 5.4% by the same concentration of genistein. H(2)O(2)-induced JNK phosphorylation and ERK phosphorylation were inhibited by staurosporine, protein kinase C (PKC) inhibitor. VK3-induced JNK phosphorylation was also blocked, but ERK phosphorylation was not affected. Staurosporine had no effect on VK3- or H(2)O(2)-induced growth inhibition. Treatment with a non-thiol antioxidant agent, catalase, completely abrogated H(2)O(2)-induced JNK and ERK phosphorylation, but a thiol antioxidant, L: -cystein, had no effect on phosphorylation of them. The VK3-induced JNK phosphorylation was inhibited by catalase, but not L: -cystein. But ERK phosphorylation was not inhibited by catalase and was abrogated completely by the thiol antioxidant. Catalase, but not L: -cystein, blocked H(2)O(2)-induced growth inhibition, and L: -cystein, but not catalase, blocked VK3-induced effects on cell proliferation completely.
CONCLUSION: VK3-induced ERK phosphorylation occurs by a different mechanism from oxidative stress, and it might have an important role to induce growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922126     DOI: 10.1007/s00280-007-0610-9

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

1.  SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons.

Authors:  Ying Li; Wei Xu; Michael W McBurney; Valter D Longo
Journal:  Cell Metab       Date:  2008-07       Impact factor: 27.287

Review 2.  Reactive oxygen species in cancer.

Authors:  Geou-Yarh Liou; Peter Storz
Journal:  Free Radic Res       Date:  2010-05

3.  Thymoquinone, a bioactive component of Nigella sativa, normalizes insulin secretion from pancreatic β-cells under glucose overload via regulation of malonyl-CoA.

Authors:  Joshua P Gray; Delaine Zayasbazan Burgos; Tao Yuan; Navindra Seeram; Rebecca Rebar; Rebecca Follmer; Emma A Heart
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-01-19       Impact factor: 4.310

4.  Fibroblasts from long-lived mutant mice show diminished ERK1/2 phosphorylation but exaggerated induction of immediate early genes.

Authors:  Liou Y Sun; Michael J Steinbaugh; Michal M Masternak; Andrzej Bartke; Richard A Miller
Journal:  Free Radic Biol Med       Date:  2009-09-26       Impact factor: 7.376

5.  Cytotoxic and apoptotic effects of menadione on rat hepatocellular carcinoma cells.

Authors:  Pinar Oztopcu-Vatan; Muge Sayitoglu; Melek Gunindi; Emine Inan
Journal:  Cytotechnology       Date:  2014-05-15       Impact factor: 2.058

6.  Novel therapy for locally advanced triple-negative breast cancer.

Authors:  Atsuko Yamada; Shinji Osada; Toshiyuki Tanahashi; Satoshi Matsui; Yoshiyuki Sasaki; Yoshihiro Tanaka; Naoki Okumura; Nobuhisa Matsuhashi; Takao Takahashi; Kazuya Yamaguchi; Kazuhiro Yoshida
Journal:  Int J Oncol       Date:  2015-08-05       Impact factor: 5.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.